1 / 9

Update on Prevention, Diagnosis & Treatment of Diabetic Macular Edema ( DME) Part 3

Update on Prevention, Diagnosis & Treatment of Diabetic Macular Edema ( DME) Part 3. A. Paul Chous, MA, OD, FAAO Specializing in Diabetes Eye Care & Education Tacoma, WA Adjunct Instructor, Nova Southeastern University College of Optometry

elizabethwade
Download Presentation

Update on Prevention, Diagnosis & Treatment of Diabetic Macular Edema ( DME) Part 3

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Update on Prevention, Diagnosis & Treatment of Diabetic Macular Edema (DME) Part 3 A. Paul Chous, MA, OD, FAAO Specializing in Diabetes Eye Care & Education Tacoma, WA Adjunct Instructor, Nova Southeastern University College of Optometry Principal Investigator for the Diabetes Visual Function Supplement Study (DiVFuSS)

  2. Importance of Early Treatment Lucentis Laser Mean change in BCVA from baseline (pooled) • With crossover from laser to 1 year of 0.5 mg ranibizumab therapy at third year, original sham (laser) treatment group’s visual gains were lower than those seen in first year of ranibizumab-treated groups (2.8 vs 10.6 and 11.1 letters) • Delayed treatment reduced magnitude of VA benefits of anti-VEGF therapy RISE and RIDE Research Group. Ophthalmology. 2013;120:2013-2022.

  3. Aflibercept: Mean Improvement in Best-Corrected Visual Acuity v. Laser VIVID *P < 0.0001 vs. laser ETDRS letters VISTA *P < 0.0001 vs. laser Week ETDRS; Compared to baseline; FAS; LOCF; VISTA – Laser: n=154; 2q4: n=154; 2q8: n=151 VIVID - Laser: n=132; 2q4: n=136; 2q8; n=135 Korobelnik JF, et al. Ophthalmology. 2014 Jul 8.

  4. Is It Safe???? • Meta-analysis of 2500 patients shows no significantly increased risk of CVA, MI, vascular death or mortality with Lucentis for DME (but 95% CIs = 0.37 to 4.73) • There is a dose-dependent increased risk of mortality (p = 0.04) that dissipates when Lucentis is used pro en reta to p = 0.133 Retina. 2014 Apr;34(4):629-35

  5. What anti-VEGF is Best for DME? • Avastin, Lucentis & Eylea are now being studied head-to-head – results due in 2016 (DRCR.net Protocol T) • Outcomes appear comparable by 15 RCTs and 8 observational studies, but evidence for superiority is insufficient • Cost-effectiveness is best with Avastin • Adverse events with Avastin are under-reported Int J Technol Assess Health Care. 2013 Oct;29(4):392-401

  6. Protocol T – 1 year data Diabetic Retinopathy Clinical Research Network • Aflibercept results in ‘significantly better’ VA versus ranibizumab or bevacizumab • APTC Events: Eylea = 2%, Avastin = 4%, Lucentis = 5% • Caution: 1-year data, not published Regeneron Press Release, 10/17/14 APTC = Antiplatelet Trialists Collaboration

  7. Steroids in DME • There is a significant inflammatory component to DME • Steroids result in improved vision in the short term but • Invariably result in cataract formation • Often result in increased intraocular pressure/glaucoma Improved visual acuity (more letters on eye chart) from intravitreal steroid injections wanes over time Diabetic Retinopathy Clinical Research Network, Elman MJ et al. Ophthalmology. 2010;117(6):1064-1077.e35.

  8. Intravitreal Steroid Implants • Slow release • Dexamethasone (OzurdexTM) • Lasts up to 6 mos • Fluocinolone (IluvienTM) • Lasts up to 3 years Grain of rice compared to Ozurdex™ implant • Some recent investigations such as the DRCR.net Protocol I have supported the use of combination therapy in the treatment of DME, including anti-VEGFs, laser & steroids with greater improvements in visual acuity noted* * Ophthalmology. 2010;117:1064-1077.

  9. Does Good Blood Glucose Control Even Matter Once We Start Using anti-VEGF Agents for DR/DME? YES!!

More Related